Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

I-Mab’s Bispecific Antibody Joined by BMS’s PD-1 in Gastric Cancer Trial

publication date: Jun 6, 2024

I-Mab , now a US company since selling off its China assets earlier this year, announced plans to form a clinical trial collaboration with Bristol Myers Squibb that will combine I-Mab’s givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, with BMS’s PD-1, nivolumab. The Phase I trial will examine the combination as a first-line therapy for advanced Claudin 18.2-positive gastric and esophageal cancers. Patients will also receive chemotherapy (FOLFOX or CAPOX). BMW will supply nivolumab to participants in the trial. I-Mab is jointly developing givastomig with ABL Bio of Korea. More details....

Stock Symbols: (NSDQ: IMAB) (KOSDAQ: 298380)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here